Titre : Déterminants sociaux de la santé

Déterminants sociaux de la santé : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement C5a
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Déterminants sociaux de la santé : Questions médicales les plus fréquentes", "headline": "Déterminants sociaux de la santé : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Déterminants sociaux de la santé : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-20", "dateModified": "2025-04-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Déterminants sociaux de la santé" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Santé", "url": "https://questionsmedicales.fr/mesh/D006262", "about": { "@type": "MedicalCondition", "name": "Santé", "code": { "@type": "MedicalCode", "code": "D006262", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N01.400" } } }, "about": { "@type": "MedicalCondition", "name": "Déterminants sociaux de la santé", "alternateName": "Social Determinants of Health", "code": { "@type": "MedicalCode", "code": "D064890", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mofya S Diallo", "url": "https://questionsmedicales.fr/author/Mofya%20S%20Diallo", "affiliation": { "@type": "Organization", "name": "Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles, Keck School of Medicine at the University of Southern California, 4650 Sunset Boulevard, MS#3, Los Angeles, CA 90027, USA. Electronic address: modiallo@chla.usc.edu." } }, { "@type": "Person", "name": "Sacharitha Bowers", "url": "https://questionsmedicales.fr/author/Sacharitha%20Bowers", "affiliation": { "@type": "Organization", "name": "Division of Dermatology, Department of Internal Medicine, Loyola University Medical Center, Stritch School of Medicine, 1S260 Summit Ave, Oakbrook Terrace, IL 60181, USA. Electronic address: sachbow@gmail.com." } }, { "@type": "Person", "name": "Aileen Y Chang", "url": "https://questionsmedicales.fr/author/Aileen%20Y%20Chang", "affiliation": { "@type": "Organization", "name": "Department of Dermatology, University of California San Francisco, Zuckerberg San Francisco General Hospital, 995 Potrero Avenue, Building 90, Ward 92, San Francisco, CA 94110, USA." } }, { "@type": "Person", "name": "Christina Pardo", "url": "https://questionsmedicales.fr/author/Christina%20Pardo", "affiliation": { "@type": "Organization", "name": "Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA. Electronic address: chp4022@med.cornell.edu." } }, { "@type": "Person", "name": "Julianne Holt-Lunstad", "url": "https://questionsmedicales.fr/author/Julianne%20Holt-Lunstad", "affiliation": { "@type": "Organization", "name": "Department of Psychology, Brigham Young University, Provo, Utah, USA; email: julianne_holt-lunstad@byu.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial.", "datePublished": "2022-12-24", "url": "https://questionsmedicales.fr/article/36566174", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12931-022-02278-1" } }, { "@type": "ScholarlyArticle", "name": "The case for complement component 5 as a target in neurodegenerative disease.", "datePublished": "2023-02-17", "url": "https://questionsmedicales.fr/article/36786123", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/14728222.2023.2177532" } }, { "@type": "ScholarlyArticle", "name": "Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.", "datePublished": "2023-12-01", "url": "https://questionsmedicales.fr/article/37824211", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1172/JCI168277" } }, { "@type": "ScholarlyArticle", "name": "The C5aR1 complement receptor: A novel immunomodulator of insulin action in skeletal muscle.", "datePublished": "2023-10-26", "url": "https://questionsmedicales.fr/article/37890688", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cellsig.2023.110944" } }, { "@type": "ScholarlyArticle", "name": "Thinking inside the box: intracellular roles for complement system proteins come into focus.", "datePublished": "2023-01-17", "url": "https://questionsmedicales.fr/article/36650365", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41416-022-02116-7" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Caractéristiques de la population", "item": "https://questionsmedicales.fr/mesh/D011154" }, { "@type": "ListItem", "position": 3, "name": "Santé", "item": "https://questionsmedicales.fr/mesh/D006262" }, { "@type": "ListItem", "position": 4, "name": "Déterminants sociaux de la santé", "item": "https://questionsmedicales.fr/mesh/D064890" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Déterminants sociaux de la santé - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Déterminants sociaux de la santé", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Déterminants sociaux de la santé", "description": "Comment évaluer l'impact des déterminants sociaux sur la santé ?\nQuels outils mesurent les déterminants sociaux de la santé ?\nQuels indicateurs sont utilisés pour le diagnostic social ?\nComment les inégalités sociales affectent-elles la santé ?\nQuel rôle joue l'environnement dans le diagnostic social ?", "url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5a&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Déterminants sociaux de la santé", "description": "Quels symptômes peuvent indiquer des déterminants sociaux défavorables ?\nComment la pauvreté affecte-t-elle la santé mentale ?\nQuels symptômes physiques sont liés à des conditions sociales ?\nLes inégalités sociales provoquent-elles des symptômes spécifiques ?\nComment l'accès limité aux soins se manifeste-t-il ?", "url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5a&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Déterminants sociaux de la santé", "description": "Quelles stratégies de prévention ciblent les déterminants sociaux ?\nComment sensibiliser aux déterminants sociaux de la santé ?\nQuel rôle des communautés dans la prévention ?\nComment les politiques publiques influencent-elles la prévention ?\nQuels programmes de prévention sont efficaces ?", "url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5a&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Déterminants sociaux de la santé", "description": "Comment adapter les traitements aux déterminants sociaux ?\nQuels traitements sont efficaces pour les populations défavorisées ?\nComment les services de santé peuvent-ils réduire les inégalités ?\nQuel rôle joue l'éducation dans le traitement des maladies ?\nComment les politiques de santé influencent-elles les traitements ?", "url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5a&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Déterminants sociaux de la santé", "description": "Quelles complications sont liées aux inégalités sociales ?\nComment les déterminants sociaux aggravent-ils les maladies ?\nQuels sont les effets à long terme des déterminants sociaux ?\nComment prévenir les complications liées aux déterminants sociaux ?\nLes complications de santé sont-elles évitables ?", "url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5a&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Déterminants sociaux de la santé", "description": "Quels sont les principaux facteurs de risque sociaux ?\nComment l'éducation influence-t-elle les facteurs de risque ?\nQuel impact a l'emploi sur la santé ?\nComment l'environnement social affecte-t-il la santé ?\nQuels facteurs de risque sont liés à l'accès aux soins ?", "url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5a&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'impact des déterminants sociaux sur la santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'impact peut être évalué par des études épidémiologiques et des enquêtes sociales." } }, { "@type": "Question", "name": "Quels outils mesurent les déterminants sociaux de la santé ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des questionnaires standardisés et des indices de conditions de vie sont utilisés." } }, { "@type": "Question", "name": "Quels indicateurs sont utilisés pour le diagnostic social ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les indicateurs incluent le revenu, l'éducation, et l'accès aux soins de santé." } }, { "@type": "Question", "name": "Comment les inégalités sociales affectent-elles la santé ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les inégalités sociales peuvent entraîner des disparités dans l'accès aux soins et la santé." } }, { "@type": "Question", "name": "Quel rôle joue l'environnement dans le diagnostic social ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'environnement physique et social influence la santé par l'accès aux ressources." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer des déterminants sociaux défavorables ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes de stress, dépression ou maladies chroniques peuvent apparaître." } }, { "@type": "Question", "name": "Comment la pauvreté affecte-t-elle la santé mentale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "La pauvreté peut entraîner une augmentation de l'anxiété et de la dépression." } }, { "@type": "Question", "name": "Quels symptômes physiques sont liés à des conditions sociales ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies comme l'hypertension et le diabète peuvent être exacerbées par des conditions sociales." } }, { "@type": "Question", "name": "Les inégalités sociales provoquent-elles des symptômes spécifiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des symptômes de maladies évitables et chroniques." } }, { "@type": "Question", "name": "Comment l'accès limité aux soins se manifeste-t-il ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Il se manifeste par des symptômes non traités et des complications de santé." } }, { "@type": "Question", "name": "Quelles stratégies de prévention ciblent les déterminants sociaux ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des programmes d'éducation, d'accès aux soins et de soutien communautaire sont essentiels." } }, { "@type": "Question", "name": "Comment sensibiliser aux déterminants sociaux de la santé ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Par des campagnes d'information et des formations pour les professionnels de santé." } }, { "@type": "Question", "name": "Quel rôle des communautés dans la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les communautés peuvent mobiliser des ressources et créer des réseaux de soutien." } }, { "@type": "Question", "name": "Comment les politiques publiques influencent-elles la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent promouvoir l'équité en santé et améliorer l'accès aux services." } }, { "@type": "Question", "name": "Quels programmes de prévention sont efficaces ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les programmes intégrés qui abordent plusieurs déterminants sociaux sont les plus efficaces." } }, { "@type": "Question", "name": "Comment adapter les traitements aux déterminants sociaux ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements doivent tenir compte des ressources et des conditions de vie des patients." } }, { "@type": "Question", "name": "Quels traitements sont efficaces pour les populations défavorisées ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les programmes de santé communautaire et les interventions ciblées sont efficaces." } }, { "@type": "Question", "name": "Comment les services de santé peuvent-ils réduire les inégalités ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "En offrant des soins accessibles et adaptés aux besoins des populations vulnérables." } }, { "@type": "Question", "name": "Quel rôle joue l'éducation dans le traitement des maladies ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation améliore l'adhésion aux traitements et la gestion des maladies." } }, { "@type": "Question", "name": "Comment les politiques de santé influencent-elles les traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elles déterminent l'accès aux soins et les ressources disponibles pour les traitements." } }, { "@type": "Question", "name": "Quelles complications sont liées aux inégalités sociales ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des maladies chroniques non traitées et des décès prématurés." } }, { "@type": "Question", "name": "Comment les déterminants sociaux aggravent-ils les maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent entraîner un accès limité aux soins et une mauvaise gestion des maladies." } }, { "@type": "Question", "name": "Quels sont les effets à long terme des déterminants sociaux ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent mener à des problèmes de santé persistants et à une qualité de vie réduite." } }, { "@type": "Question", "name": "Comment prévenir les complications liées aux déterminants sociaux ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "En améliorant l'accès aux soins et en renforçant les réseaux de soutien communautaire." } }, { "@type": "Question", "name": "Les complications de santé sont-elles évitables ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreuses complications peuvent être évitées par des interventions précoces." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque sociaux ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent la pauvreté, le manque d'éducation et l'isolement social." } }, { "@type": "Question", "name": "Comment l'éducation influence-t-elle les facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Une éducation supérieure est associée à une meilleure santé et à des comportements préventifs." } }, { "@type": "Question", "name": "Quel impact a l'emploi sur la santé ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un emploi stable améliore la santé mentale et physique, réduisant les risques." } }, { "@type": "Question", "name": "Comment l'environnement social affecte-t-il la santé ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Un environnement social positif favorise le bien-être et réduit les risques de maladies." } }, { "@type": "Question", "name": "Quels facteurs de risque sont liés à l'accès aux soins ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Le manque d'accès aux soins médicaux et préventifs augmente les risques de maladies." } } ] } ] }

Sources (1648 au total)

Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial.

We recently reported in the phase 3 PANAMO trial that selectively blocking complement 5a (C5a) with vilobelimab led to improved survival in critically ill COVID-19 patients. C5a is an important contri...

The case for complement component 5 as a target in neurodegenerative disease.

Complement-based drug discovery is undergoing a renaissance, empowered by new advances in structural biology, complement biology and drug development. Certain components of the complement pathway, par... We will discuss the evidence supporting C5 as a target in neurodegenerative disease, along with the current progress in developing different classes of C5 inhibitors and the gaps in knowledge that wil... Validation of C5 as a therapeutic target for neurodegenerative disease would represent a major step forward for complement therapeutics research and has the potential to furnish disease-modifying drug...

Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.

In myelin oligodendrocyte glycoprotein IgG-associated disease (MOGAD) and aquaporin-4 IgG+ neuromyelitis optica spectrum disorder (AQP4+NMOSD), the autoantibodies are mainly composed of IgG1, and comp... CSF-C3a, CSF-C4a, CSF-C5a, and CSF-C5b-9 levels during the acute phase before treatment in patients with MOGAD (n = 12), AQP4+NMOSD (n = 11), multiple sclerosis (MS) (n = 5), and noninflammatory neuro... CSF-C3a and CSF-C5a levels were significantly higher in MOGAD (mean ± SD, 5,629 ± 1,079 pg/mL and 2,930 ± 435.8 pg/mL) and AQP4+NMOSD (6,017 ± 3,937 pg/mL and 2,544 ± 1,231 pg/mL) than in MS (1,507 ± ... The complement pathway is activated in both MOGAD and AQP4+NMOSD, but MAC formation is lower in MOGAD, particularly in those with mild attacks, than in AQP4+NMOSD. These findings may have pathogenetic...

Serum Depletion of Complement Component 5a Is Associated With Increased Inflammation and Poor Clinical Outcomes in Patients With Perianal Fistulas.

Persistent disease is a significant issue in the management of perianal fistulas, with up to 50% of patients requiring additional treatment after surgery.... This study aimed to identify a novel prognostic modality in hopes of risk-stratifying patients for persistent disease following corrective surgery.... This was a retrospective study based on prospectively collected data using a combination of histopathology, high-throughput proteomic arrays, and ELISA-based methods.... This study used data obtained from patients who underwent corrective surgery for perianal fistulas at the University of Illinois Hospital between June 2019 and July 2020.... A cohort of 22 consecutive patients who had corrective surgery for perianal fistulas were included in this study. The patients were divided into 2 groups: those with resolving fistulas (N = 13) and th... Nonresolving fistulas were determined by disease representation within 2 months of corrective surgery.... Serum samples from patients with persistent perianal fistulas displayed a consistent decrease in the expression of complement pathway component C5a compared with either healthy controls or patients wi... This study was limited by its retrospective design, relatively small sample size, and single-center data analysis.... These results suggest that C5a is modestly depleted in patients with nonresolving forms of disease and traffics to the site of tissue damage and inflammation. Accordingly, serum C5a warrants continued... ANTECEDENTES:La persistencia de la enfermedad es un problema significativo en el manejo de las fístulas perianales, presente hasta en el 50 % de los pacientes después de la cirugía y que requieren tra...

Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer's disease of different severity.

Alzheimer's disease (AD) is a common cause of dementia. Serum complement factor 5a (C5a) is exceedingly implicated in AD. We explored the role of C5a levels in AD patients of different severity.... Mild, moderate, and severe AD patients, and healthy controls were included. C5a and pro-inflammatory factor (TNF-α, IL-1β, IL-6, CRP) levels were assessed by ELISA, and cognitive function was evaluate... Serum C5a, TNF-α, IL-1β, IL-6 and CRP levels were raised, and MMSE score was lowered in AD. Serum C5a, TNF-α, IL-1β, IL-6 and CRP levels in severe AD patients were higher than those in mild/moderate A... Serum C5a level increased with AD severity, and its expression was positively correlated with serum pro-inflammatory factor levels, and negatively correlated with cognitive function....

Dysregulated complement activation during acute myocardial infarction leads to endothelial glycocalyx degradation and endothelial dysfunction via the C5a:C5a-Receptor1 axis.

Complement-mediated damage to the myocardium during acute myocardial infarction (AMI), particularly the late components of the terminal pathway (C5-convertase and C5b-9), have previously been characte... Samples of fifty-five patients with ST-elevation myocardial infarction (STEMI) vs. healthy controls were analyzed in this study. eGC components and C5a levels were determined via ELISA; NO levels were... Serum concentrations of eGC components and C5a were significantly increased during STEMI. Serum and solely C5a stimulation decreased eGC height and stiffness, indicating shedding of the eGC. C5a enhan... This study demonstrates that dysregulated C5a activation during AMI results in eGC damage with subsequent endothelial dysfunction and reduced NO bioavailability, indicating progressively developing va...